S. La Rosa

Discipline

Psychologie (2) Economies et finances (2) Histoire, Philosophie et Sociologie des sciences (1) Anthropologie biologique (1)

Type de document

Articles (53) Recensions (12)

Co-auteur

Date

Source

Mot-clé

Tumors (33) Cancer (31) Patients (25) Patients (25) Cases (21) Human beings (21) Cases (21) Cancer (18) Cells (18) cancer (17) Treatment (15) Prognosis (14) Expression (14) Prognosis (14) Diagnosis (13) Diagnosis (13) Tumors (13) analyse (11) Analysis (11) Case (10) Pancreas (10) Grammar, Comparative and general--Case (10) Case (10) spectacle (9) survie (9) Survival (9) Series (9) Addition (9) thérapie (8) littérature (8)

Documents écrit par S. La Rosa (53) | parle de S. La Rosa (0)

AKAP2-anchored protein phosphatase 1 controls prostatic neuroendocrine carcinoma cell migration and invasion.
E. Reggi et al.
Assessing cancer risk in the anterior part of the prostate using micro-ultrasound: validation of a novel distinct protocol.
S. Schaer et al.
PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas.
G. Cossu et al. (8 sept. 2023)
Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identity.
R. Sanalkumar et al. (31 mars 2023)
Do cancer detection rates differ between transperineal and transrectal micro-ultrasound mpMRI-fusion-targeted prostate biopsies? A propensity score-matched study.
A. Rakauskas et al. (2023)
BRAF Rearrangements and BRAF V600E Mutations Are Seen in a Subset of Pancreatic Carcinomas With Acinar Differentiation.
T. Ghosh et al. (1 juil. 2022)
Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases.
A. Vanoli et al.
EWSR1-ATF1 dependent 3D connectivity regulates oncogenic and differentiation programs in Clear Cell Sarcoma.
E. Möller et al. (27 avr. 2022)
Neuroblastic Tumors of the Adrenal Gland in Elderly Patients: A Case Report and Review of the Literature.
P. Deslarzes et al. (2022)
Low number of neurosecretory vesicles in neuroblastoma impairs massive catecholamine release and prevents hypertension.
A. Mühlethaler-Mottet et al. (2022)
Infirmière clinicienne de centre du cancer : l’expérience du Centre de la prostate du CHUV [Cancer center clinical nurse: The experience of the CHUV Prostate Cancer Center]
C. Codeluppi et al. (1 déc. 2021)
Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis: Review of Published Cases.
A. Roukain et al. (6 sept. 2021)
Classification of neuroendocrine neoplasms: lights and shadows.
S. La Rosa et al.
Intron 4-5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance.
C. Ricci et al.
Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
A. Rakauskas et al.
A live single-cell reporter assay links intratumor heterogeneity to metastatic proclivity in Ewing sarcoma.
T. Keskin et al.
Prise en charge des sarcomes des tissus mous abdominaux [Management of abdominal soft tissue sarcomas]
R. Djafarrian et al. (16 juin 2021)
Testosterone-induced increase in libido in a patient with a loss-of-function mutation in the AR gene.
L. Marino et al. (1 juin 2021)
Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms.
S. La Rosa
Carcinome anaplasique de la thyroïde : nouvelles approches thérapeutiques [Anaplastic thyroid carcinoma : new therapeutic approaches]
A. Stamatiou et al. (19 mai 2021)
Primary glomus tumour of the pituitary gland: diagnostic challenges of a rare and potentially aggressive neoplasm.
B.L. Quah et al.
Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades.
M. Simbolo et al. (23 avr. 2021)
Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study.
E. Karamitopoulou et al.
Does Mixed Neuroendocrine-Nonneuroendocrine Neoplasm (MiNEN) of the Parathyroid Gland Exist? First Description of a Possible Case.
S. Di Palma et al.
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.
W.A. Mampuya et al.

next